Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

BETHESDA and GAITHERSBURG, Md., Nov. 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) and MedImmune, Inc. today announced that new data from an ongoing Phase 1 clinical trial of MT103 in patients with late- stage non-Hodgkin's lymphoma (NHL) will be presented at the 2007 Annual Meeting of the American Society of Hematology (ASH) on December 9 in Atlanta, Georgia. MT103, also known as MEDI-538, is a recombinant T-cell engaging antibody, or BiTE(R) antibody, targeting the CD19 antigen, which is uniquely expressed on B-cells. As the first BiTE antibody studied in humans, MT103 is currently being evaluated in Phase 1 and 2 clinical trials for the treatment of patients with various B-cell malignancies.

New data from the ongoing Phase 1 dose-escalating trial show evidence of objective complete and partial responses in relapsed follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) patients. At the time of the analysis, dose levels tested ranged from 0.0005 to 0.030 mg/m2 per day, respectively. Among the 15 evaluable patients at dose levels of 0.015 and 0.030 mg/m2 per day, two complete responses, two partial responses, and two minimal responses were observed. One of the complete responses was in a patient with MCL. In addition, six patients experienced stable disease and three patients progressed during treatment. The full data set, which will include additional patients at a higher dose level than reported in the abstract, will be presented at ASH.

Six patients at dose levels 0.015 and 0.030 mg/m2 per day had tumor infiltration in the bone marrow, a location from which relapses of these diseases potentially emanate. The bone marrow infiltration in five out of si
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... 31, 2015 , ... According to an article published August 3rd ... adolescents who underwent bariatric surgery “felt significantly better two years after surgery.” The article ... in the study felt that their “mental health had been normalized” at the point ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... AdvantaClean franchise business with a ribbon-cutting ceremony on Aug. 26, generously hosted by ... and booking inspection appointments via AdvantaClean’s National Call Center and website since Aug. ...
(Date:8/31/2015)... ... 31, 2015 , ... American Family Care (AFC), the nation’s ... presence in Tennessee with the opening of a new urgent care facility at ... sixteenth in Tennessee, and 148th in the U.S. overall. , “We’re excited to ...
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito ... and assess their competencies in managing challenging conversations, announced today that Glenn Albright, ... Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit ...
(Date:8/31/2015)... Village, IL (PRWEB) , ... August 31, 2015 , ... ... new studies, Etymotic Research, maker of the BEAN™ personal sound amplifier, is offering caregivers ... personal sound amplifiers as a way of coping with a variety of home healthcare ...
Breaking Medicine News(10 mins):Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3
... culprit for infertility in women according to a recent research ... young people are infected with the microorganism. It is feared ... far higher//. ,The number of young women tested ... margin of three times over the past three years. Chlamydia ...
... before the age of 16 developed eating disorders and had ... Research had shown that a study conduced in 10,000 women ... of 16 developed later in their life symptoms of eating ... much about weight gain and change in body shape after ...
... potentially fatal cancers, according to a new case study published ... ,A researcher at the University of Nevada has shown that ... or golden algae oil, can save the life of a ... a professor of biochemistry and associate director of the Nevada ...
... warned of serious outbreaks of acute watery diarrhoea among quake ... up efforts to provide safe water supply and sanitation in ... have been recorded among earthquake survivors in the tent camps ... devastated by the Oct 8 temblor. ,However, there has ...
... DNA of chimps and humans share a 98% similarity and ... can be used to find out the reasons for some ... not to chimpanzees//. , ,Susceptibility to Malaria, Bacterial resistance ... which can be studied due to genetic difference as both ...
... rather unusual but very practical study was conducted in ... the American College of Surgeons in San Francisco reveals ... surgery recover sooner than those who do not//. ... resection surgery. The patients were divided into two groups: ...
Cached Medicine News:Health News:One In Nine Young Women Diagnosed With Chlamydia Infection 2Health News:Pakistani Quake Survivors Face Outbreak Of Diarrhea 2
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... announced a strategic collaboration focused on the development, ... active pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s ... their expertise in developing and manufacturing controlled substance ... to tech transfer processes into these facilities. The ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... Cancer Therapeutics CRC,Pty Ltd (CTx) has commenced ... its type in the world. Underpinned by ... million from the Australian Commonwealth Government, CTx addresses,the ... and its,ability to discovery and develop new drugs ...
... Pain Conditions; Compound ... -, LA JOLLA, Calif., Aug. 27 TorreyPines,Therapeutics, ... has initiated a,Phase I multiple dose clinical trial to ... a subcutaneous injection to,healthy male and female volunteers once-daily ...
Cached Medicine Technology:New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs 2New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs 3TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 2TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 3TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel 4
Inquire...
... Small Bone Power System combines precision ... under the most exacting conditions. The ... small bone osteotomies and oral/maxillofacial procedures ... Length Available), Oscillating Saw (Extended Length ...
... System is a specialized electric system ... designed for use in Otolaryngology, Neurosurgery, ... System consists of a specialized electric ... designed to provide precision and control ...
... The Brasseler USA™ Battery ... quickly and efficiently determine ... STR-2000, STR-3000 Extended Run, ... Driver™, Battery Packs contain ...
Medicine Products: